Filing Details
- Accession Number:
- 0001415889-24-018204
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-26 16:00:05
- Reporting Period:
- 2024-06-25
- Accepted Time:
- 2024-06-26 16:00:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 59478 | Eli Lilly & Co | LLY | Pharmaceutical Preparations (2834) | 350470950 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 316011 | Lilly Endowment Inc | 2801 North Meridian Street Indianapolis IN 46208-0068 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-06-25 | 57,563 | $902.27 | 97,499,347 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 62,127 | $903.56 | 97,437,220 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 46,359 | $904.52 | 97,390,861 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 4,019 | $905.40 | 97,386,842 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 4,806 | $906.40 | 97,382,036 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 6,763 | $907.28 | 97,375,273 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 5,610 | $908.60 | 97,369,663 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 853 | $909.06 | 97,368,810 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $902.00 to $902.96, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $903.00 to $903.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $904.00 to $904.92, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $905.00 to $905.94, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $906.00 to $906.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $907.00 to $907.90, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $908.00 to $908.995, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $909.00 to $909.10, inclusive.
Billionaire Hedge Funds
